NFE2L2 and hepatocellular carcinoma: Sorafenib and erastin can activate the NFE2L2 pathway, resulting in the expression of antioxidant genes such as quinone oxidoreductase 1 (NQO1) and metallothionein 1G (MT1G) in HCC cells (87, 89).